Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RENB 
Renovaro Biosciences Inc (RENB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: RENB (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
0 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Year Target Price $0
Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 85.6% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 50.38M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.53 | 52 Weeks Range 0.27 - 2.10 | Updated Date 06/29/2025 |
52 Weeks Range 0.27 - 2.10 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -8.41% | Return on Equity (TTM) -53.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 55777031 | Price to Sales(TTM) - |
Enterprise Value 55777031 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -7.37 | Shares Outstanding 172119008 | Shares Floating 90925076 |
Shares Outstanding 172119008 | Shares Floating 90925076 | ||
Percent Insiders 47.27 | Percent Institutions 12.85 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Renovaro Biosciences Inc
Company Overview
History and Background
Renovaro Biosciences Inc. (formerly known as BioVie Inc.) is a biotechnology company focused on developing therapies for cancer and infectious diseases. It has undergone strategic shifts, including mergers and acquisitions, to refine its focus on innovative therapies.
Core Business Areas
- Immunotherapy: Developing immunotherapies to target cancer by leveraging the body's immune system.
- Cell Therapy: Exploring cell-based therapies to treat cancer.
Leadership and Structure
The company is led by a board of directors and a management team with experience in biotechnology and pharmaceuticals. Specific leadership details are publicly available through Renovaro's investor relations website.
Top Products and Market Share
Key Offerings
- REN001: An immunotherapy being developed for pancreatic cancer. It is currently in clinical trials. No current market share available as it's not yet approved. Competitors include companies developing similar immunotherapy approaches, such as Bristol Myers Squibb (BMY) and Merck (MRK).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high R&D costs, regulatory hurdles, and intense competition. Significant growth is expected in cancer immunotherapy and cell therapies.
Positioning
Renovaro Biosciences is positioned as a developer of innovative cancer therapies, focusing on areas with unmet medical needs. Their competitive advantage depends on the success of their clinical trials and the efficacy of their therapies.
Total Addressable Market (TAM)
The global cancer therapy market is projected to reach hundreds of billions of dollars. Renovaro Biosciences aims to capture a portion of this market with its innovative therapies. The positioning of the company is speculative due to products not being approved yet.
Upturn SWOT Analysis
Strengths
- Novel immunotherapy approaches
- Focus on unmet medical needs
- Experienced management team
- Strategic partnerships
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- High R&D costs
- No products currently generating revenue
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Accelerated regulatory pathways
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory challenges
- Economic downturn
Competitors and Market Share
Key Competitors
- BMY
- MRK
- PFE
- JNJ
Competitive Landscape
Renovaro faces intense competition from larger pharmaceutical companies with greater resources. Their success depends on innovation and clinical trial outcomes.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in the company's strategic shifts and acquisitions, as well as progress in its clinical programs.
Future Projections: Future growth is dependent on the successful development and commercialization of its therapies.
Recent Initiatives: Recent initiatives may include ongoing clinical trials, partnerships, and presentations at scientific conferences.
Summary
Renovaro Biosciences is a development-stage company focused on innovative cancer therapies. Its success hinges on positive clinical trial results and securing partnerships. The company faces challenges due to limited resources and competition, requiring careful management of R&D and strategic initiatives. Future growth prospects depend on successful navigation of regulatory hurdles and market acceptance of its therapies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Investor Relations
- Market Research Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual research and consultation with a financial advisor. Market share data is estimated and may not reflect precise figures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Renovaro Biosciences Inc
Exchange NASDAQ | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2015-02-02 | CEO & Director Mr. David H. Weinstein | ||
Sector Healthcare | Industry Biotechnology | Full time employees 25 | Website https://renovarogroup.com |
Full time employees 25 | Website https://renovarogroup.com | ||
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company has a strategic collaboration with Nebul to advance the early detection of cancer and other diseases. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.